How is hyaluronic acid measured?

Hyaluronic acid (HA) is a non-sulfated glycosaminoglycan composed of repeating disaccharide units of D-glucuronic acid and N-acetyl-D-glucosamine, and it is the same polymer referred to in the literature as hyaluronan or hyaluronate. In research and formulation work it is not described by a single number: the evidence block for this page characterises HA-containing materials by molecular weight, by concentration in a formulation, and by stability of that molecular weight over time, rather than by one universal assay. The studies cited here report HA as a component of hydrogels, dermal fillers, oral supplements, mouthwash formulations and nanoparticle carriers, and each of those contexts measures it differently.

The mechanistic work in this evidence set centres on oxidative chain scission of the HA polymer and on the inflammatory signalling pathways — principally NF-κB and the NLRP3–TXNIP–iNOS axis — that HA-containing formulations are tested against in cartilage and joint models.

Research Studies

Hyaluronic acid and oxidative chain scission in a model wound-healing material

HA-based hydrogels are used as wound-healing materials and topical delivery systems because of their biocompatibility, water retention and ability to promote cell migration. HA is prone to oxidative chain scission, which reduces molecular weight and compromises formulation stability and functional performance. One study evaluated ergothioneine as a candidate antioxidant stabilising excipient in a model HA-based wound-healing material. Biocompatibility of ergothioneine was assessed by CCK-8 assay in L929 mouse fibroblasts after 24 hours of exposure, alongside a stress-screening framework including Fenton oxidation and high-temperature/high-humidity conditions [2]. This is an in vitro study using a mouse fibroblast line; it does not establish behaviour in human tissue.

Ectoine and NF-κB signalling in chondrocytes and a rat osteoarthritis model

Osteoarthritis is characterised by inflammation and cartilage destruction, partly mediated by IL-1β-induced NF-κB activation. Ectoine is a natural osmoprotectant with anti-inflammatory properties. In this study, primary rat chondrocytes were pretreated with ectoine (0–3.0% w/v) and then stimulated with IL-1β (10 ng/mL), with cell viability evaluated and gene expression measured by RT-qPCR and Western blotting; the compound was also tested in a rat model of osteoarthritis [3]. The chondrocyte work is in vitro and the joint work is in a rat model.

Niacinamide-enriched cross-linked HA dermal filler and collagen stimulation

Biological skin ageing involves flattening of the epidermal–dermal junction and reduced collagen types I and III. One study evaluated the biostimulatory, antimicrobial, anti-inflammatory and safety profiles of a niacinamide-enriched cross-linked hyaluronic acid dermal filler compared with untreated controls and Belotero Balance® [4]. This is a formulation-comparison study of a filler material, not a measurement of endogenous HA in humans.

REJENERA and the NLRP3–TXNIP–iNOS axis in a rat osteoarthritis model

REJENERA is a multi-component nutraceutical formula containing olive leaf bioflavonoids (ZeyEX, quercetin and luteolin), S-allylcysteine, palmitoylethanolamide, L-proline, hyaluronic acid and boron. One study compared its efficacy in knee osteoarthritis against ZeyEX, NPROC (collagen-rich eggshell membrane combined with olive leaf extract) and ibuprofen in a rat model, with osteoarthritis established by intra-articular injection of monosodium iodoacetate (3 mg) into the right knee joint [5]. HA is one component of a multi-component formula here, so the study does not isolate an HA-specific effect.

Chlorhexidine mouthwash with N-acetylcysteine and HA in human gingival fibroblasts

An in vitro study is evaluating the effects of two chlorhexidine-based mouthwash formulations on the survival and function of human gingival fibroblasts. Fibroblasts obtained from discarded gingival tissue collected during routine dental procedures are cultured and exposed to different concentrations of a conventional 0.2% chlorhexidine mouthwash and a 0.2% chlorhexidine mouthwash supplemented with N-acetylcysteine and hyaluronic acid. Cell viability, apoptosis, migration and gene expression are assessed at multiple time points using Trypan Blue exclusion, fluorescence-activated cell sorting, scratch assay and quantitative RT-PCR [6]. This is an in vitro human cell study.

Oral HA-containing supplement and HPV DNA integration in women with persistent infection

An interventional, single-centre, open-label randomised clinical study is evaluating an oral dietary supplement (Pervistop®) in women with persistent human papillomavirus infection. The supplement combines epigallocatechin gallate, folic acid, vitamin B12 and hyaluronic acid. The primary objective is to describe the effect of this combination on HPV DNA integration into the host genome by measuring the clearance rate of viral oncoproteins E6 and E7. Forty-two women aged 25 or older with persistent HPV infection and low-grade cervical lesions are randomised 1:1 into two groups [7]. HA is one of four molecules in the supplement, and the outcome measured is viral oncoprotein clearance, not HA concentration.

HA and folic acid-modified mesoporous silica nanoparticles delivering sulforaphane in NSCLC

Sulforaphane suppresses NSCLC metastasis by modulating miR-616-5p, which is transcriptionally upregulated by SPI1. In this study, SPI1 expression in NSCLC tissues positively correlated with miR-616-5p levels, and SPI1 transcriptionally regulated miR-616-5p to promote NSCLC cell invasion and migration. Sulforaphane was found to bind SPI1 directly, inhibiting its activity and downregulating miR-616-5p. Because sulforaphane has poor stability, the authors developed a delivery system using hyaluronic acid and folic acid-modified mesoporous silica nanoparticles [8]. Here HA functions as a targeting and delivery component of a nanoparticle, and its role is defined by the nanoparticle construct rather than by a standalone measurement.

Oral HA drink and knee pain in a registered trial

A registered trial is evaluating the effect of an A+HA premium oral hyaluronic acid drink on relieving knee pain [1]. The endpoint is a pain measure in participants consuming an oral HA drink, not a laboratory quantification of HA.

Comparison of measurement contexts across the evidence set

Across these studies, HA is characterised in three broad ways: as a polymer whose molecular weight can be tracked and lost through oxidative chain scission [2]; as a component of a formulation whose performance is judged by biological or clinical endpoints [1][4][5][6][7]; and as a targeting or structural element in a delivery construct [8]. None of the evidence here provides a single reference method for measuring HA itself.

If you are reading this for personal health reasons

The materials described on this page are sold for laboratory research use only. We do not provide dosing, medical guidance or recommendations for personal use of any compound. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] A+HA Premium Oral Hyaluronic Acid Drink Functional Evaluation Trial for Delaying Joint Pain
• [2] Effect of Ergothioneine on the Stability of Hyaluronic Acid-Based Wound-Healing Materials
• [3] Ectoine Inhibits IL-1β-Induced Inflammation by Suppressing the NF-κB Pathway in Chondrocytes and Alleviates Osteoarthritis in a Rat Model
• [4] A smarter dermal filler: Antimicrobial protection and collagen stimulation with niacinamide
• [5] REJENERA©, a multi-component bioflavonoid-based formula, alleviates osteoarthritis and provides chondroprotection by regulating the NLRP3-TXNIP-iNOS axis and inflammation
• [6] Effects of Chlorhexidine on Human Gingival Fibroblasts
• [7] Effect of EGCG, Folic Acid, Vitamin B12 and Hyaluronic Acid on HPV DNA Integration
• [8] Hyaluronic acid and folic acid-modified mesoporous silica nanoparticles delivering sulforaphane suppress NSCLC via SPI1/miR-616-5p axis